We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Tucatinib Against Stage IV HER2+ Breast Cancer, Phase III Trial Results Promising

News   Dec 12, 2019 | Original story from University of Colorado Cancer Center

 
Tucatinib Against Stage IV HER2+ Breast Cancer,  Phase III Trial Results Promising
 
 
 

RELATED ARTICLES

Global Efforts To Contain Antibiotic Resistant Infections Under Threat

News

According to the World Health Organization, a weak development pipeline for new antibiotics is undermining efforts to combat drug-resistant infections.

READ MORE

Common Drug Counteracts Treatment Resistance in Patients With Leukemia

News

A new study suggests that a common and inexpensive drug may be used to counteract treatment resistance in patients with acute myeloid leukemia (AML).

READ MORE

Magnetized Molecules Help Monitor Breast Cancer

News

A new type of scan has been developed that involves magnetizing molecules – it allows physicians to observe in real-time which regions of a breast tumor are active.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE